The development and launch of Liverscan® by Eieling Technology Limited, a PolyU start-up led by Ir Prof. ZHENG Yongping, Director of the Research Institute for Smart Ageing (RISA), Henry G. Leong Professor in Biomedical Engineering and Chair Professor of Biomedical Engineering, has revolutionised screening technologies for liver diseases and is giving patients more hope for early diagnosis and treatment, particularly in disadvantaged areas.
In response to the healthcare resource shortages in poverty-stricken areas, Eieling Technology collaborates proactively with local governments and district health centres in conducting charity activities and providing free screenings for fatty liver disease and liver fibrosis in neighbourhoods. Liverscan® has already obtained registration approval from the US Food and Drug Administration (FDA510K) and NMPA medical device registration in mainland China in 2024. Currently, around 30 sets of Liverscan® have been installed for clinical use in Hong Kong, Macao, and different cities in Mainland China. The company plans to install 100,000 devices worldwide in the next five years, especially in developing countries and poor areas, and this will significantly promote the adoption of liver disease screening to reduce severe liver problems, such as cirrhosis or liver cancer. In addition, Eieling Technology launched its five-year “LiverCare—Hong Kong 10 Million Liver Scans” program at the Asia Summit on Global Health in May 2024, together with PolyU and a number of local partners. PolyU formally launched its screening program for liver health for all full-time staff in December 2024.
